General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving Average of $2.44 | news.google.com • |
Arbutus Biopharma (NASDAQ:ABUS) Stock Crosses Above 200-Day Moving Average of $2.44 | news.google.com • |
Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue? | news.google.com • |
What technical indicators reveal about ABUS stock – US Post News | news.google.com • |
Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options | news.google.com • |
Arbutus Biopharma Engages Investors at May Conferences- TipRanks | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-02 | 2024-03 | -0.1 | -0.1 | N/A | N/A |
2024-02-29 | 2023-12 | -0.12 | -0.12 | N/A | N/A |
2023-11-07 | 2023-09 | -0.12 | -0.12 | N/A | N/A |
2023-08-03 | 2023-06 | -0.12 | -0.1 | 0.02 | 16.67% |
2023-05-04 | 2023-03 | -0.14 | -0.1 | 0.04 | 28.57% |
2023-03-02 | 2022-12 | -0.14 | -0.14 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-03 | Chardan Capital | Upgrade | Buy | Buy |
2023-07-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-05 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
2023-06-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2016-08-15 | ABRAMS MICHAEL J | Officer | 42.10K | Conversion of Exercise of derivative security |
2023-01-31 | COLLIER WILLIAM H. | Chief Executive Officer | 216.50K | Stock Award(Grant) |
2024-02-01 | HASTINGS DAVID C | Chief Financial Officer | 181.91K | Sale |
2023-01-31 | HOWARD ELIZABETH ANN | Officer | 86.02K | Stock Award(Grant) |
2024-02-01 | MC ELHAUGH MICHAEL JOHN | Chief Executive Officer | 1.50M | Sale |
2018-11-27 | MURRAY MARK J | Director | 341.40K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 9.97M | 22.93M | 5.95% |
2023-06-29 | Two Seas Capital Lp | 8.28M | 19.05M | 4.94% |
2023-06-29 | Whitefort Capital Management, LP | 8.09M | 18.62M | 4.83% |
2023-06-29 | Vanguard Group Inc | 5.82M | 13.38M | 3.47% |
2023-06-29 | Morgan Stanley | 5.08M | 11.68M | 3.03% |
2023-06-29 | Rubric Capital Management LP | 3.40M | 7.81M | 2.03% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.30M | 7.59M | 1.97% |
2023-08-30 | iShares Russell 2000 ETF | 2.73M | 5.54M | 1.63% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.61M | 3.70M | 0.96% |
2023-07-30 | Fidelity Small Cap Index Fund | 1.09M | 2.37M | 0.65% |
2023-08-30 | iShares NASDAQ Biotechnology ETF | 861.37K | 1.75M | 0.51% |
2023-06-29 | Morgan Stanley Inst Fund Inc-Inception Port | 750.71K | 1.73M | 0.45% |
Split | Date |
---|---|
0.2 : 1 | 2010-11-04 |
Another tard
3.75 today
It’s such a casual part of the process... Do we even need to devote much funds as Moderna to create an LNP? It just magically appears. WTF you talking about?? Dear god.
Modernas LNP research division was set up when?
When is moderna gonna spin off their LNP division? Or when did they have funds going to that so called division??! Dear god.
Vaccines work. On the scale of 10’s of billions now given. Thank god for them. Boogie man = dumbfuck weirdos at this point
When the term “of from”” is used it is for a reason
Buqqets = tard Neither. Dear god. Dumbfucks still arguing reality. Billions of shots have been safely delivered. The recipients of the shots factually have super human immunity.
Ready for launch
Billions of shots delivered. Ill stick with the facts.
Ripe and ready for
I love them both
Ready for
Vivek is a tard.
Ready for launch
Moderna preemptively tried to invalidate patents and lost. So honest…
ARBUTUS = TARD
Moderna has warned of a "substantial risk" that Arbutus could invoke its '069 patent in an infringement suit targeting its COVID-19 vaccine
Bottom is in
Bottom is in